What is hC Bioscience?
Based in Cambridge, MA, hC Bioscience is a biotechnology company founded in 2021, specializing in the development of tRNA therapies. The company's focus on this innovative area of genetic medicine positions it at the forefront of therapeutic advancements. Its establishment in a prominent biotech hub like Cambridge suggests access to a rich ecosystem of research talent and potential collaborators, crucial for a company at its development stage.
How much funding has hC Bioscience raised?
hC Bioscience has raised a total of $36M across 2 funding rounds:
Unspecified
$12M
Series A
$24M
Unspecified (2021): $12M, investors not publicly disclosed
Series A (2022): $24M led by 8VC, Takeda Ventures, and ARCH VENTURE PARTNERS
Key Investors in hC Bioscience
Takeda Ventures
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company, focusing on investments in innovative healthcare and life sciences companies.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
8VC
8VC is a venture capital firm that invests in companies building the future, with a focus on technology and life sciences.
What's next for hC Bioscience?
The substantial enterprise-level funding, including the recent strategic investment, provides hC Bioscience with the necessary capital to accelerate its research and development pipeline. This infusion of financing is expected to support the progression of its tRNA therapy candidates through preclinical and clinical trials. The company's strategic focus and the backing from prominent investors indicate a clear trajectory towards becoming a key player in the biotechnology landscape, potentially leading to further growth and market expansion.
See full hC Bioscience company page
